PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

Biotech Day
CPHI 2027
AI in Drug Discovery
Auto Draft
Auto Draft
Auto Draft
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Advertisement

Fujifilm

Aurisco

Established in 1998, Aurisco is an innovative pharmaceutical company engaged in research, development, manufacturing and marketing of specialty APIs, formulations as well as CRDMO service. With 6 R&D centers and opening its 4th cGMP manufacturing site, the company has offices in USA, Portugal, China, India and Brazil. Aurisco has been deeply involved in the pharmaceutical industry for more than 26 years and commits itself to continuous technological innovation and sustainability. Having passed 5 cGMP inspections in 2023 (USFDA/EUGMP/PMDA/NMPA/KFDA), Aurisco Pharmaceutical is expanding with new workshops for peptides (Semaglutide, Tirzepatide) and Oligonucleotides (New oligoprocess flexfactory for ASOs and siRNAs) and a new manufacturing site in 2025, growing its toolbox of technologies, small molecule API offer and unbeatable CRDMO services for oligonucleotides and peptides. Today, the company plays a leading role in China and global markets in the field of complex synthesis, synthetic biology, photochemistry and continuous flow chemistry. Aurisco is Ecovadis Gold ranked and joined the SBTi with a target of becoming carbon neutral by 2027, reaching zero emissions by 2030, being a reliable long-term partner of the well-known pharmaceutical companies worldwide. Our focus on customer service, mature quality system, regulatory experience, growing production capacity and global sales network enables the company to provide high-quality products and efficient service to our customers around the world.

Commercial APIs API Name DMF(Drug Mater File)
Abiraterone AcetateEU,US,CANADA,CHINA,JAPAN, BRAZIL 
ApalutamideUS, CHINA
Bempedoic AcidEU, US, CHINA
Betamethasone ValerateEU(CEP), CANADA
BrivaracetamEU, US, CANADA, CHINA
Elagolix EU, US  
EnzalutamideEU, US, CHINA
Eplerenone EU(CEP), US, CANADA, JAPAN
Finerenone US, EU
DydrogesteroneEU(CEP), US, CHINA
Fluticasone PropionateEU(CEP), US, CHINA
Fluticasone FuroateEU(CEP), US, CHINA
Mometasone FuroateEU(CEP), US
Nusinersen (ASO, Oligonucleotides)DMF Ready
Pregabalin EU(CEP), US, CANADA, CHINA 
Relugolix US
SemaglutideUS
TDF (Tenofovir Disoproxil Fumarate)EU, US, CHINA
TAF (Tenofovir Alafenamide Hemifumarate)EU, US, CHINA
TMF(Tenofovir Alafenamide Monofumarate)EU, US, CHINA
Vibegron US

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC